Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease

Despite potential impact on the graft vs. leukemia (GVL) effect, immunotherapy targeting CTLA-4 and/or PD-1 has not been successfully combined with bone marrow transplant (BMT) because it exacerbates graft vs. host disease (GVHD). Here, using models of GVHD and leukemia, we demonstrate that targetin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Christopher, Wei, Yuanyi, Yan, Jinsong, Huang, Dan, Zhang, Peng, Qi, Chong, Lazarski, Christopher, Su, JuanJuan, Tang, Fei, Wong, Chun-shu, Zheng, Pan, Liu, Yan, Liu, Yang, Wang, Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694596/
https://www.ncbi.nlm.nih.gov/pubmed/37827154
http://dx.doi.org/10.1016/j.xcrm.2023.101236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694596/
https://www.ncbi.nlm.nih.gov/pubmed/37827154
http://dx.doi.org/10.1016/j.xcrm.2023.101236

Ejemplares similares